Apr. 6 at 4:27 PM
$SLS - Aza approved years ago, on Generic Pricing, Ven 2017 approval - window closing - Current Pricing for the Last 3 AML Approved Drugs
- Do the MATH - Buy SLS, your future YOU will thank you.
- "The Kura Q4 earnings call characterized Revuforj's annual WAC as "almost
$1 million a year" due to its dosing schema and SKU structure"
- "The menin inhibitor pricing gap (~
$600K vs. ~
$1M annually) has already become a payer access flashpoint, with at least some plans beginning to implement step edits favoring ziftomenib first."
-- Events are NOT Linear this far along in a OS trial for AML Cr2 Patients, who are Ineligible for Transplant - with inherent co-morbidities and the 2 to 5 year time in trial for those remaining alive, mean we could see Events in Spates and the Top Line Results ANY DAY NOW. https://www.reddit.com/r/sellasLifescience/comments/1sdpysk/events_are_not_linear_this_far_along_in_a_os/?share_id=vDnR6Nqf6rYL2WJS5gHiE&utm_content=2&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1
